Companion Animal Health Products: 2006 edition

Table of Contents

CHAPTER 1 COMPANION ANIMAL HEALTH PROBLEMS

• 1.1 Infectious diseases
  • 1.1.1 Canine infectious diseases
    • 1.1.1.1 Bordetella bronchiseptica
    • 1.1.1.2 Coronavirus
    • 1.1.1.3 Distemper
    • 1.1.1.4 Hepatitis
    • 1.1.1.5 Influenza
    • 1.1.1.6 Kennel cough
    • 1.1.1.7 Leptospirosis
    • 1.1.1.8 Lyme isease
    • 1.1.1.9 Parvovirus
    • 1.1.1.10 Rabies
    • 1.1.1.11 Feline infectious diseases
    • 1.1.1.12 Feline influenza
    • 1.1.1.13 Chlam ydophila
    • 1.1.1.14 Feline infectious peritonitis
    • 1.1.1.15 Feline leukaemia
    • 1.1.1.16 Panleukopenia
    • 1.1.1.17 Feline immunodeficiency virus
  • 1.1.2 Equine infectious diseases
    • 1.1.2.1 African horse sickness
    • 1.1.2.2 Equine encephalom yelitis
    • 1.1.2.3 Equine infectious anaemia
    • 1.1.2.4 Equine influenza
    • 1.1.2.5 Equine protozoal myeloencephalitis
    • 1.1.2.6 Equine viral arteritis
    • 1.1.2.7 Equine viral rhinopneumonitis
    • 1.1.2.8 Strangles
    • 1.1.2.9 Tetanus
    • 1.1.2.10 West Nile virus
• 1.2 Parasitic infections
  • 1.2.1 Endoparasites
    • 1.2.1.1 Gastrointestinal nem atodes
    • 1.2.1.2 Heartworms
    • 1.2.1.3 Horse bots
    • 1.2.1.4 Lungworms
    • 1.2.1.5 Protozoa
    • 1.2.1.6 Tapeworms
  • 1.2.2 Ectoparasites
    • 1.2.2.1 Fleas
    • 1.2.2.2 Ticks
    • 1.2.2.3 Mites
    • 1.2.2.4 Lice
    • 1.2.2.5 Flies
• 1.3 Musculoskeletal problems
  • 1.3.1 Canine osteoarthritis
  • 1.3.2 Equine lameness
• 1.4 Cardiovascular disease
  • 1.4.1 Cong estive heart failure
  • 1.4.2 Deg enerative valve disease
  • 1.4.3 Cardiom yopathy
• 1.5 Cancer
  • 1.5.1 Mast cell tumors

CHAPTER 2 COMPANION ANIMAL PRODUCTS

• 2.1 Introduction
• 2.2 Anti-infectives
  • 2.2.1 Anti-infective product g roups
    • 2.2.1.1 Am inog lycosides
    • 2.2.1.2 Penicillins
    • 2.2.1.3 Macrolides
    • 2.2.1.4 Lincosamides
    • 2.2.1.5 Tetracyclines
    • 2.2.1.6 Chloramphenicol and derivatives
    • 2.2.1.7 Sulfonamides
    • 2.2.1.8 Cephalosporins
    • 2.2.1.9 Fluoroquinolones
  • 2.2.2 Recent developments
    • 2.2.2.1 New antibiotic active ingredients
      • Cefpodoxime
      • Difloxacin
      • I bafloxacin
      • Marbofloxacin
      • Ofloxacin
      • Orbifloxacin
  • 2.2.3 Future developments
  • 2.2.3.1 Anticipated launch activity
• 2.3 Antiparasitics
  • 2.3.1 Endoparasiticides
  • 2.3.1.1 Endoparasiticide product groups
    • I m idazothiazoles
    • Benzim idazoles
    • Tetrahydropyrim idines
    • Macrocyclic lactones
    • Cyclic depsipeptides
    • Others
  • 2.3.1.2 Recent developments
    • Emodepside
    • Generic penetration
    • Parasite vaccines
  • 2.3.1.3 Future prospects
  • 2.3.1.4 Ectoparasiticide product groups
    • Org anophosphates
    • Carbamates
    • Form amidines
    • Pyrethrins and pyrethroids
    • I nsect growth regulators
    • Phenylpyrazoles
    • Neonicotinoids
    • Recent developments
    • Fipronil
    • Imidacloprid
    • Lufenuron
    • Nitenpyram
    • Pyriproxyfen
    • Future prospects
  • 2.3.1.5 Endectocides
    • Selam ectin
    • Quasi-endectocides
    • Future developments
• 2.4 Anti-inflammatories
  • 2.4.1 Anti-inflam m atory product g roups
    • 2.4.1.1 Corticosteroids
    • 2.4.1.2 Non-steroidal anti-inflammatory drugs
      • Established NSAI Dclasses
      • The coxib NSAI Dsubclass
  • 2.4.2 Recent developments
    • 2.4.2.1 Carprofen
    • 2.4.2.2 Deracoxib
    • 2.4.2.3 Etodolac
    • 2.4.2.4 Firocoxib
    • 2.4.2.5 Meloxicam
    • 2.4.2.6 Tepoxalin
  • 2.4.3 Future prospects
• 2.5 Other pharm aceuticals
  • 2.5.1 Cardiovascular drugs
    • 2.5.1.1 ACE inhibitors
      • Enalapril
      • Benazepril
      • Ramipril
      • Imidapril
      • Alacepril
      • Temocapril
    • 2.5.1.2 Other cardiovascular drugs
  • 2.5.2 Behavioral therapies
  • 2.5.3 Gastrointestinal drugs
  • 2.5.4 Others
  • 2.5.5 Future prospects
    • 2.5.5.1 Cardiovasculars
    • 2.5.5.2 Behavioral therapies
    • 2.5.5.3 Gastrointestinal drugs
    • 2.5.5.4 Others
• 2.6 Biologicals
  • 2.6.1 Biolog ical product groups
    • 2.6.1.1 Canine vaccines
    • 2.6.1.2 Feline vaccines
    • 2.6.1.3 Equine vaccines
    • 2.6.1.4 Diag nostics
  • 2.6.2 Recent developments
    • 2.6.2.1 Sm all animal vaccines
    • 2.6.2.2 Equine vaccines
    • 2.6.2.3 Diag nostics
  • 2.6.3 Future prospects

CHAPTER 3 MAJOR NATIONAL MARKETS FOR COMPANION ANIMAL PRODUCTS

• 3.1 Australia
  • 3.1.1 The Australian market for animal health products
  • 3.1.2 The market for companion animal health products
  • 3.1.3 Companion animal market structure
  • 3.1.4 Companion animal market prospects in Australia
• 3.2 Brazil
  • 3.2.1 The Brazilian market for animal health products
  • 3.2.2 The market for companion animal health products
  • 3.2.3 Companion animal market structure
  • 3.2.4 Companion animal market prospects in Brazil
• 3.3 Canada
  • 3.3.1 The Canadian market for animal health products
  • 3.3.2 The market for companion animal products
  • 3.3.3 Structure of the Canadian companion animal market
  • 3.3.4 Companion animal market prospects in Canada
• 3.4 France
  • 3.4.1 The French market for animal health products
  • 3.4.2 The market for companion animal products
  • 3.4.3 Structure of the French companion animal market
    • Antiparasitics
    • Other pharm aceuticals
    • Biologicals
  • 3.4.4 Companion animal market prospects in France
• 3.5 Germ any
  • 3.5.1 The Germ an market for animal health products
  • 3.5.2 The market for companion animal health products
  • 3.5.3 Companion animal market structure
  • 3.5.4 Companion animal market prospects in Germ any
• 3.6 Italy
  • 3.6.1 The Italian market for animal health products
  • 3.6.2 The market for companion animal health products
  • 3.6.3 Companion animal market structure
  • 3.6.4 Companion animal market prospects in Italy
• 3.7 Japan
  • 3.7.1 The Japanese market for animal health products
  • 3.7.2 The market for companion animal health products
  • 3.7.3 Companion animal market structure
  • 3.7.4 Companion animal market prospects in Japan
• 3.8 Spain
  • 3.8.1 The Spanish market for animal health products
  • 3.8.2 The market for companion animal health products
  • 3.8.3 Companion animal market structure
  • 3.8.4 Companion animal market prospects in Spain
• 3.9 United King dom
  • 3.9.1 The UK market for animal health products
  • 3.9.2 The market for companion animal products
  • 3.9.3 Structure of the companion animal products market
    • Antiparasitics
    • Other pharm aceuticals
    • Biologicals
  • 3.9.4 Companion animal market prospects in the UK
• 3.10 United States of Am erica
  • 3.10.1 The US market for animal health products
  • 3.10.2 The market for companion animal products
  • 3.10.3 Companion animal market structure
    • Antiparasitics
    • Other pharm aceuticals
    • Biologicals
  • 3.10.4 Companion animal market prospects in the US
    • New products and patent expiries

CHAPTER 4 THE GLOBAL MARKET FOR COMPANION ANIMAL PRODUCTS

• 4.1 The g lobal market for animal health products
• 4.2 The g lobal market for companion animal health products
• 4.3 Companion animal product sales by reg ion
• 4.4 Major national markets for companion animal products
• 4.5 Market drivers and constraints
  • 4.5.1 Companion animal populations
    • Developed countries
    • Developing countries
  • 4.5.2 Econom ic, social and demographic trends
    • Economic growth
    • Developed countries
    • Developing countries
    • Social and demographic trends
  • 4.5.3 New products and technologies
    • Market impact
  • 4.5.4 Prom otion and marketing techniques
  • 4.5.5 Companion animal health and disease trends
  • 4.5.6 Patent expiries and generic penetration
    • Ivermectin
    • Other recent generic targets
    • Future generic targets
  • 4.5.7 Product safety issues
    • ProHeart 6
    • NSAI Ds
    • Lessons for the industry
  • 4.5.8 Regulatory factors
    • Market impact
  • 4.5.9 Companion animal health insurance
• 4.6 Future growth of the companion animal products market

CHAPTER 5 COMPANY PROFILES

• 5.1 Introduction
• 5.2 Bayer
  • 5.2.1 Company backg round
  • 5.2.2 Companion animal business
  • 5.2.3 Major companion animal products
    • Other antiparasitics
    • Enrofloxacin
  • 5.2.4 Future developments
• 5.3 Fort Dodg e
  • 5.3.1 Company backg round
  • 5.3.2 Companion animal business
  • 5.3.3 Major companion animal products
    • Vaccines
    • Antiparasitics
    • Other pharm aceuticals
  • 5.3.4 Future developments
• 5.4 Idexx
  • 5.4.1 Company background
  • 5.4.2 Companion animal business
  • 5.4.3 Major companion animal products
    • Rapid assays
    • Pharm aceuticals
  • 5.4.4 Future developments
  • 5.5 I ntervet
  • 5.5.1 Company backg round
  • 5.5.2 Companion animal business
  • 5.5.3 Major companion animal products
    • Vaccines
    • Anti-infectives
    • Antiparasitics
    • Other pharm aceuticals
  • 5.5.4 Future developments
• 5.6 Merial
  • 5.6.1 Company backg round
  • 5.6.2 Companion animal business
  • 5.6.3 Major companion animal products
    • Fipronil
    • Ivermectin
    • Other pharm aceuticals
    • Biologicals
  • 5.6.4 Future developments
• 5.7 Novartis
  • 5.7.1 Company backg round
  • 5.7.2 Companion animal business
  • 5.7.3 Major companion animal products
    • Antiparasitics
    • Anti-inflammatories and dermatological treatments
    • Others
  • 5.7.4 Future developments
• 5.8 Pfizer
  • 5.8.1 Company backg round
  • 5.8.2 Companion animal business
  • 5.8.3 Major companion animal products
    • Anti-infectives
    • Antiparasitics
    • Other pharm aceuticals
    • Vaccines
  • 5.8.4 Future developments
• 5.9 Schering -Ploug h
  • 5.9.1 Company backg round
  • 5.9.2 Companion animal business
  • 5.9.3 Major companion animal products
    • Anti-infectives
    • Anti-inflammatories
    • Antiparasitics
    • Vaccines
    • Others
  • 5.9.4 Future developments
• 5.10 Vetoquinol
  • 5.10.1 Company backg round
  • 5.10.2 Companion animal business
  • 5.10.3 Major companion animal products
    • Anti-infectives
    • Other pharmaceuticals
    • Nutraceuticals
  • 5.10.4 Future developments
• 5.11 Virbac
  • 5.11.1 Company backg round
  • 5.11.2 Companion animal business
  • 5.11.3 Major companion animal products
    • Antiparasitics
    • W orm ers
    • I nsecticides
    • Other pharmaceuticals
    • Biologicals
  • 5.11.4 Future developments